Contact us Demo our platform

ON-DEMAND WEBINAR

Blood-Based Biomarkers—How Metabolomics Assists Stroke Research to Improve Diagnosis and Monitoring

Like many neurological diseases, signs and symptoms of stroke vary widely in a given population. Both delayed diagnosis and ineffective treatment can have devastating consequences for victims of stroke and stroke-like diseases. Metabolomics provides an opportunity to tease apart this complex problem and moves the field toward precision medicine. Join Dr. Steffen Tiedt, M.D., Ph.D., Principal Investigator and Senior Physician at the Institute for Stroke and Dementia Research, Munich, as he guides us through his applications of metabolomics to stroke research. From identifying biomarkers of stroke for accurate diagnosis to applying a systems biology approach to examining the consequences of stroke, metabolomics, used in tandem with other omics, can derive actionable insights to improve both diagnosis and treatment for stroke patients.

During this webinar, you will learn:

  • How metabolomics can be a powerful tool for studying biomarkers in stroke
  • The benefits of outsourcing metabolomics experiments
  • How metabolic signatures can be used to understand current disease state
  • What types of follow-up questions can result from a metabolomics study

About Metabolomics

Metabolomics plays a critical role in understanding heterogeneous diseases like stroke by providing a snapshot of dynamic metabolic processes in biological systems. In neurological diseases like stroke, it can provide insight into the pathophysiology, making progress toward improved diagnosis which could lead to prevention. By analyzing the metabolome, scientists can discover novel biomarkers. On the other end of the disease process, metabolomic signatures, in combination with other omics, can improve understanding of disease progression and inform personalized treatment strategies to improve patient outcomes. Metabolomics offers a valuable tool to bridge the gap between molecular processes and clinical manifestations, paving the way for advancements in our ability to study, diagnose, and manage neurological diseases like stroke.

K
L

Dr. Steffen Tiedt, M.D., Ph.D.

Dr. Steffen Tiedt is a Principal Investigator and Senior Physician at the Institute for Stroke and Dementia Research, Munich, aiming to identify circulating signatures that inform on the local and systemic effects of stroke.

Dr. Tiedt studied medicine at Ludwig Maximilian University of Munich and Harvard University. Intrigued by courses on neurophysiology, he conducted his M.D. thesis with Dr. Magdalena Götz, exploring the role of STAT-signalling on the neurogenic potential of reactive astrocytes. In 2013, Dr. Tiedt joined the group of Martin Dichgans at the ISD as a clinician-scientist conducting a joint program: a Ph.D. in Neuroscience at the Graduate School of Systemic Neuroscience and residency in Clinical Neurology. During his Ph.D. work, he initiated the CIRCULAting biomarkers after Stroke (CIRCULAS) and PRecisiOn Medicine In StrokE (PROMISE) studies, which by now are among the largest studies world-wide with early and serial blood sampling in acute stroke patients (N > 2,000). Utilizing this resource, Dr. Tiedt and his team were the first to employ RNA sequencing for the identification of circulating miRNAs associated with stroke and to apply single-molecule array (Simoa™) technology during the course of stroke (publications in Circulation Research and Neurology).

Based on this work, Dr. Tiedt’s lab now utilizes profiling, ultrasensitive single-molecule, and point-of-care technologies to identify meaningful signatures to improve stroke care and explores underlying molecular and pathophysiological mechanisms in experimental settings.

Blood-Based-Biomarkers-WEBINAR

WATCH THE WEBINAR

Related Webinars

See All Webinars
✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.